Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

作者：Lila Adnane, Pamela A. Trail, Ian C. A. Taylor, Scott M. Wilhelm · 发表于：Methods in enzymology on CD-ROM/Methods in enzymology · 年份：2006 · DOI：10.1016/s0076-6879(05)07047-3 · 被引用次数：475 · 研究领域：Melanoma and MAPK Pathways、Cancer Mechanisms and Therapy、PI3K/AKT/mTOR signaling in cancer